QUEST is a FREE newsletter published three times a year by the Urological Research Foundation. It informs readers of the latest advances in urologic research, especially prostate cancer treatment.
Please click here to subscribe to QUEST.
QUEST is a free newsletter, but we appreciate your support in helping the URF bring this publication to its readers.
The ACS said that at least 18% of all cancers and about 16% of cancer deaths in the U.S. are related to excess body weight, lack of physical activity, alcohol consumption, and/or poor nutrition. Following the ACS recommendations could potentially…
A number of laboratories studies have suggested that mushrooms have a preventative effect on a number of cancers, including prostate cancer. In addition, these studies have demonstrated beneficial effects of mushrooms on health, such as antioxidant effects that prevent chronic…
The drug studied in the trial was ipilimumab (brand name Yervoy). The drug is used in patients with metastatic melanoma. It is thought to enhance the body’s immune response by activating T cells, which help fight cancer cells. Cancers such…
Dr. Catalona Argues that Biopsies are Still Necessary in Active Surveillance Dr. Catalona participated in a plenary session at the conference entitled Crossfire: Controversies in Urology: Prostate Cancer Active Surveillance Can be Done with mpMRI and Biomarkers; Biopsies are No…
by Betsy Haberl For 25 years, Chris’ PSA score had been high. But in 2015, he had missed a couple of annual PSA tests, and his latest PSA came back very elevated. Suspecting prostate cancer, his urologist performed a biopsy….
by William J. Catalona, M.D. One of my concerns is that there are very limited rigorous long-term cancer control data on robotic surgery. The most important outcome should be cancer control. Furthermore, authors have speculated that the high-pressure insufflation with…
The theory behind using PSA to stratify future prostate cancer risk—and subsequently adjusting PSA screening—is based on data showing that men with higher PSA levels in midlife, also called a baseline PSA, were more like to develop prostate cancer up…
Family History of Breast Cancer is a Risk Factor for Prostate Cancer An analysis of 18 studies involving more than 17 million people found that a history of breast cancer in first-degree relatives was associated with an 18% increased risk…
The two drugs are olaparib (brand name Lynparza) and rucaparib (brand name Rubraca). Both of these PARP inhibitors have been the focus of scientific research in recent years and the approvals are advancements in precision medicine treatments for prostate cancer….
Androgen-deprivation therapy (ADT) suppresses levels of androgens, including testosterone, because these hormones can fuel the spread of cancer. Thus, lowering the amounts of these hormones can control the spread of prostate cancer. However, there is an association between ADT in…